Clinical trials
Recherche d’études cliniques
Recherchez uniquement dans les études cliniques enregistrées dans Biomedical Watch.
Études cliniques 612
| Étude / NCT ⇅ | Molécule ⇅ | Maladie ⇅ | Phase ⇅ | Statut ⇅ | Résultat ⇅ | Sponsor ⇅ | Pays / centres ⇅ | Période ⇅ | Détail |
|---|---|---|---|---|---|---|---|---|---|
| NCT03599245 This is an Extension Study of the Roche P-trials to Investigate Safety … |
Ocrelizumab | SEP | Phase 3 | COMPLETED | En attente / non publié | Hoffmann-La Roche | Argentina, Belgium, Brazil, Bulgaria, Canada, Croatia… | 2018-07-12 → 2025-07-17 | Ouvrir |
| NCT06590545 IDEAL — Anti-CD 19 CAR-T Cell Therapy in Patients With ANCA Vasculitis |
KYV-101, an autologous fully-huma… | SEP | Phase 1/2 | NOT_YET_RECRUITING | En attente / non publié | David Simon | Non communiqué | 2025-01 → 2027-07 | Ouvrir |
| NCT06500273 ALPHA3 — Consolidation of First-Line MRD+ Remission With Cema-cel in Pa… |
cemacabtagene ansegedleucel | SEP | Phase 2 | RECRUITING | En attente / non publié | Allogene Therapeutics | United States, Australia, Canada, South Korea · Adven… | 2024-06-18 → 2032-12 | Ouvrir |
| NCT07443137 CAR-T ceLL for Eradication of Active Residual Disease in LBCL (CLEAR-1 … |
rapcabtagene autoleucel (YTB323) | SEP | Phase 1 | NOT_YET_RECRUITING | En attente / non publié | Stanford University | Non communiqué | 2026-09 → 2028-08 | Ouvrir |
| NCT05691153 ThisCART19A for B-NHL Relapsed After Auto-CAR T |
ThisCART19A with Dose Level 1 | SEP | Phase 1 | UNKNOWN | En attente / non publié | The First Affiliated Hospital of … | China · The First Affiliated Hospital of Soochow Univ… | 2022-12-01 → 2025-11-30 | Ouvrir |
| NCT07360288 TC011_FL_201 — Efficacy and Safety of TC011 in Relapsed or Refractory F… |
TC011 single-arm | SEP | Phase 2 | NOT_YET_RECRUITING | En attente / non publié | TICAROS Co., Ltd. | Non communiqué | 2026-03-01 → 2030-02-28 | Ouvrir |
| NCT06420154 The Safety and Efficacy of Anti-CD19 CAR-T Cells in Patients With Relap… |
anti-CD19-CAR-T cells | SEP | Phase 1 | NOT_YET_RECRUITING | En attente / non publié | First Affiliated Hospital of Wenz… | China · The First Affiliated Hospital of Wenzhou Medi… | 2024-05-27 → 2027-05-27 | Ouvrir |
| NCT04499573 Bispecific CD19/CD22 CAR-T for Treatment of Children and Young Adults W… |
CD19/CD22 CAR-T | SEP | Phase 1/2 | ACTIVE_NOT_RECRUITING | En attente / non publié | Federal Research Institute of Ped… | Russia · Federal Research Institute of Pediatric Hema… | 2020-07-27 → 2027-03-13 | Ouvrir |
| NCT03810196 CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infect… |
CliniMACS Cell Processing System … | SEP | Non applicable | RECRUITING | En attente / non publié | Children's Hospital of Philadelph… | United States · Children's Hospital of Philadelphia, … | 2019-03-01 → 2028-07 | Ouvrir |
| NCT07188558 PiNACLE-H2H — A Study to Investigate Ronde-cel Versus Investigator's Ch… |
rondecabtagene autoleucel | SEP | Phase 3 | RECRUITING | En attente / non publié | Lyell Immunopharma, Inc. | United States · AdventHealth, Orlando, United States … | 2026-01-12 → 2032-01 | Ouvrir |
| NCT00434629 Safety and Efficacy of Bexxar Therapy in the Treatment of Relapsed/Resi… |
Bexxar | SEP | Phase 1 | COMPLETED | En attente / non publié | University of Pennsylvania | United States · Abramson Cancer Center, University of… | 2007-02 → 2015-05 | Ouvrir |
| NCT06248086 A Study to Find a Suitable Dose of ASP2802 in People With CD20-positive… |
ASP2802 | SEP | Phase 1 | TERMINATED | En attente / non publié | Astellas Pharma Global Developmen… | Australia · Site AU61004, Sydney, Australia | 2024-09-06 → 2024-12-01 | Ouvrir |
| NCT00006669 Rituximab Followed by Combination Chemotherapy in Treating Patients Wit… |
Rituximab | SEP | Phase 2 | WITHDRAWN | En attente / non publié | National Cancer Institute (NCI) | United States · Franklin Square Hospital Center, Balt… | 1999-09 → 2000-01 | Ouvrir |
| NCT02772822 A Study Comparing the Efficiency and Safety of S-CHOP(Cyclophosphamide,… |
SCT400 plus CHOP | SEP | Phase 3 | UNKNOWN | En attente / non publié | Sinocelltech Ltd. | China · Cancer Hospital Chinese Academy of Medical Sc… | 2016-06 → 2019-12 | Ouvrir |
| NCT03636503 Rituximab + Immunotherapy in Follicular Lymphoma |
Rituximab | SEP | Phase 1 | TERMINATED | En attente / non publié | National Cancer Institute (NCI) | United States · City of Hope, Duarte, United States |… | 2018-10-30 → 2023-07-30 | Ouvrir |
| NCT04696432 A Study of C-CAR039 Treatment in Subjects With r/r NHL SubjectsNon-Hodg… |
Prizloncabtagene Autoleucel | SEP | Phase 1 | COMPLETED | En attente / non publié | Peking Union Medical College Hosp… | China · Tianjin Medical University Cancer Institute &… | 2020-11-27 → 2023-12-30 | Ouvrir |
| NCT04655677 A Study of C-CAR039 Treatment in Subjects With r/r NHL SubjectsNon-Hodg… |
Prizloncabtagene Autoleucel | SEP | Phase 1 | COMPLETED | En attente / non publié | Peking Union Medical College Hosp… | China · Peking Union Medical College Hospital, Beijin… | 2020-10-30 → 2024-06-30 | Ouvrir |
| NCT05800977 ELEVATION — A Study of C-CAR039 (Prizloncabtagene Autoleucel) in Patien… |
Prizloncabtagene Autoleucel | SEP | Phase 1/2 | RECRUITING | En attente / non publié | Peking Union Medical College Hosp… | China · Beijing Cancer Hospital, Beijing, China | Bei… | 2023-02-22 → 2028-06-30 | Ouvrir |
| NCT04693676 A Study of C-CAR039 Treatment in Subjects With r/r NHL Subjects Non-Hod… |
Prizloncabtagene Autoleucel | SEP | Phase 1 | UNKNOWN | En attente / non publié | Peking Union Medical College Hosp… | China · The First Affiliated Hospital, College of Med… | 2020-08-03 → 2024-04-30 | Ouvrir |
| NCT05149391 A Study of C-CAR039 in Subjects With Relapsed and/or Refractory B Cell … |
CD19/CD20-directed Chimeric Antig… | SEP | Phase 1 | COMPLETED | En attente / non publié | Peking University | China · Peking University Cancer Hospital, Beijing, C… | 2021-07-20 → 2024-05-30 | Ouvrir |
| NCT04317885 A Study Evaluating Safety and Efficacy of C-CAR039 Treatment in NHL Sub… |
Prizloncabtagene Autoleucel | SEP | Phase 1 | COMPLETED | En attente / non publié | Peking Union Medical College Hosp… | China · Shanghai Tongji Hospital, Tongji University S… | 2019-11-05 → 2023-12-30 | Ouvrir |
| NCT06590246 A Study to Evaluate C-CAR031 in Glypican-3 (GPC3)+ Advanced/Recurrent H… |
Armored and GPC3-targeted autolog… | SEP | Phase 1/2 | RECRUITING | En attente / non publié | Shanghai AbelZeta Ltd. | China · The First Affiliated Hospital, Zhejiang Unive… | 2024-09-30 → 2043-04-30 | Ouvrir |
| NCT07444281 An Phase I Trial of a CAR T-cell Infusion C-CAR031 in Participants With… |
C-CAR031 | SEP | Phase 1 | RECRUITING | En attente / non publié | Shanghai AbelZeta Ltd. | China · Shanghai Chest hospital, Shanghai, China | 2024-12-25 → 2028-01-30 | Ouvrir |
| NCT05155189 A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection… |
C-CAR031 | SEP | Phase 1 | RECRUITING | En attente / non publié | Shanghai AbelZeta Ltd. | China · The First Affiliated Hospital of Zhengzhou Un… | 2022-02-21 → 2041-05 | Ouvrir |
| NCT06830577 Intra-ureteric Aminophylline Instillation on Flexible Ureteroscopy Proc… |
Usage of Aminophylline prior to u… | SEP | Non applicable | RECRUITING | En attente / non publié | Ain Shams University | Egypt · Ain Shams University Hospitals, Cairo, Egypt | 2025-03-01 → 2026-02-01 | Ouvrir |